Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
Background The widespread use of immune checkpoint inhibitors (ICIs) has revolutionised
treatment of multiple cancer types. However, selecting patients who may benefit from ICI …
treatment of multiple cancer types. However, selecting patients who may benefit from ICI …
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
The gut microbiota modulates immune processes both locally and systemically. This
includes whether and how the immune system reacts to emerging tumours, whether …
includes whether and how the immune system reacts to emerging tumours, whether …
Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open …
Background In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib
showed superior progression-free survival, overall survival, and objective response over …
showed superior progression-free survival, overall survival, and objective response over …
Management of metastatic clear cell renal cell carcinoma: ASCO guideline
WK Rathmell, RB Rumble… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
European association of urology guidelines on renal cell carcinoma: the 2019 update
B Ljungberg, L Albiges, Y Abu-Ghanem, K Bensalah… - European urology, 2019 - Elsevier
Abstract Context The European Association of Urology Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …
Guideline Panel has prepared evidence-based guidelines and recommendations for the …
[HTML][HTML] Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
L Derosa, MD Hellmann, M Spaziano, D Halpenny… - Annals of …, 2018 - Elsevier
Background The composition of gut microbiota affects antitumor immune responses,
preclinical and clinical outcome following immune checkpoint inhibitors (ICI) in cancer …
preclinical and clinical outcome following immune checkpoint inhibitors (ICI) in cancer …
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Background Treatment for renal cell carcinoma has been revolutionised by inhibitors of
VEGF receptor. Previous studies have suggested that treatment with a VEGF receptor …
VEGF receptor. Previous studies have suggested that treatment with a VEGF receptor …
[HTML][HTML] Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
MB Atkins, NM Tannir - Cancer treatment reviews, 2018 - Elsevier
There has been significant progress in the treatment of patients with advanced clear cell
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …
[HTML][HTML] The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
Immune-checkpoint inhibitors (ICI) now represent the standard of care for several cancer
types. In pre-clinical models, absence of an intact gut microbiome negatively impacted ICI …
types. In pre-clinical models, absence of an intact gut microbiome negatively impacted ICI …